Trials / Completed
CompletedNCT00848926
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 102 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | brentuximab vedotin | 1.8 mg/kg every 3 weeks by intravenous infusion |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2010-08-01
- Completion
- 2015-05-01
- First posted
- 2009-02-20
- Last updated
- 2017-03-13
- Results posted
- 2011-10-26
Locations
27 sites across 5 countries: United States, Belgium, Canada, France, Italy
Source: ClinicalTrials.gov record NCT00848926. Inclusion in this directory is not an endorsement.